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The interaction of activated leukocytes and renal resident cells are thought to play a 
crucial role in the pathogenesis of renal diseases.  Recent investigations of the 
pathophysiological roles of chemokines and their cognate receptors have shed light on 
the detailed molecular mechanisms of leukocyte trafficking and activation in the 
diseased kidneys.  Chemokine/chemokine receptor systems may be essentially involved 
in the pathogenesis of phase-specific renal disorders and the measurement of urinary 
levels of chemokines may be clinically useful for monitoring the different disease 
phases and activities.  In addition, chemokine receptors expressed in renal resident cells 
may be involved in proliferation, fibrogenesis as well as chemotaxis. The selective 
intervention of chemokines/chemokine receptor systems (anti-chemokine therapy) may 
have the potential as the particular therapeutic strategies for renal diseases in future. 




 The interaction between leukocytes and renal resident cells may provide the key 
roles to the progression of the inflammatory processes.  Moreover, leukocyte trafficking 
from peripheral blood into the diseased kidneys is a hallmark of almost any kind of 
renal diseases (1).  Activated leukocytes are thought to play a crucial role in the 
pathogenesis of renal diseases from acute phases to chronic phases (2). Recent 
investigations of the pathophysiological roles of chemokines and their cognate receptors 
have shed light on the detailed molecular mechanisms of leukocyte trafficking and 
activation in various diseases (3-5). In addition, these chemokines exert overlapping but 
distinct actions on specific cell types through interacting with the cognate G protein-
coupled receptors with seven transmembrane domains (2-5).  Chemokine receptors are 
expressed not only on leukocytes, but also parenchymal cells, suggesting the possible 
autocrine/paracrine loop during the interaction of leukocytes and parenchymal cells.   
Therefore, detailed mechanisms of leukocyte recruitment and activation via 
chemokines/chemokine receptor systems may provide the better understanding of the 
pathogenesis of renal diseases. 
 This review will focus on 1) chemokine/chemokine receptor systems in the 
pathogenesis of phase-specific renal disorders (“chemokine cascade”),  and 2) the 
measurement of urinary levels of chemokines useful for monitoring the different disease 
phases and activities of human renal diseases, and 3) the intervention of 
chemokines/chemokine receptor systems as the particular immunotherapeutic strategies 
to combat with the specific phases of renal diseases. 
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Chemokine superfamily  
Chemotaxis and leukocyte activation 
 The chemokine superfamily is divided into four groups depending on conserved 
cysteine residues that form disulfide bonds in the chemokine tertiary structure (3-5).  
More than 40 chemokines and 17 chemokine receptors have been identified. Leukocyte 
trafficking at the inflammatory site consists of two major functions: first, the arrest, 
activation and firm adhesion of leukocytes on endothelial surfaces and, second, the 
diapedesis and transmigration through the endothelial cells into the renal tissue and 
from there to specific microenvironments (3-5).  Evidence is accumulating that 
chemokines through their cognate receptors are of importance for these steps.  In 
addition, during the first step, a selectin-mediated rolling followed by an integrin-
mediated firm adhesion are involved when leukocytes bind to endothelium (6-7).  
Chemokines expressed on the surface of endothelial cells interact with their cognate 
receptors on specific leukocytes, which trigger the activation of adhesion molecules and 
result in firm adhesion.  Once leukocytes migrate into the interstitium, chemokines 
produced by both tissue cells and infiltrated cells induce a variety of biological 
functions of leukocytes at the inflammatory sites.  Selective expression of chemokine 
receptors contributes to cell specificity of chemokine actions.  Thus, the chemokine 
systems provide sequential migratory patterns of the specific leukocytes with their 
cognate receptors in a multistep manner.   
 
Other biological functions of chemokines 
 Recent studies revealed that chemokines through their cognate receptors act as 
growth factors for mesangial cells (8) and are involved in respiratory burst, 
hematopoiesis, angiogenesis, development and fibrogenesis (3-5). Interferon-inducible 
protein (IP)-10 induced the proliferation of mesangial cells probably via the cognate 
receptor, CXCR3 (8). In addition, interleukin (IL)-8 and monocyte chemoattractant 
protein (MCP)-1 (also termed as monocyte chemotactic and activating factor 
(MCAF/MCP-1)) are closely related to the urinary excretion of protein in experimental 
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models (9-10) and human nephrotic syndrome (11), which may be related to the 
permeability of the glomerular capillaries.  IL-8 has been shown to induce the migration 
of human umbilical endothelial cells and angiogenesis in rat cornea (12-13).  Additional 
interest in chemokines and their cognate receptors is arising from recent identification 
of several chemokines as inhibitors and receptors as co-receptors for HIV infection 
(14).  The blockade of chemokines/chemokine receptors as the clinical therapeutic 
applications have been anticipated in these fields.  
 
In vitro expression of chemokines and chemokine receptors 
 Renal parenchymal cells express chemokine receptors as well as their cognate 
ligands on stimulation (2).  In vitro studies revealed that proinflammatory stimuli such 
as IL-1β, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, immune complexes, 
growth factors including platelet-derived growth factor and basic fibroblast growth 
factor are able to induce IL-8, MCP-1, IP-10, macrophage inflammatory protein (MIP)-
1α and regulated upon activation, normal T cell expressed and excreted (RANTES) 
from renal resident cells (2).  In turn, these stimuli may induce the expression of CCR1 
and CXCR3 on renal resident cells, especially on mesangial cells (8, 15).  These results 
suggest the certain roles of possible positive feedback loop dependent on 
chemokines/chemokine receptors which results in progressive renal diseases.  In fact, 
the C-X-C chemokines, MIP-2 and KC up-regulated MCP-1 and RANTES expression 
in mesangial cells (16).  Autoinduction of MIP-2 and KC mRNA were also noted.  
These indicate chemokine amplification probably via their cognate receptors in 
mesangial cells, which may contribute to the maintenance and chronic course of 
glomerular inflammation. In addition, vasoactive agents especially angiotensin (AG) II 
through its receptors can induce chemokine expression (17-18).  In contrast, 
glucocorticoids, transforming growth factor (TGF)-β, Vitamin D and prostaglandins are 
able to inhibit the expression of chemokines (3-5). Supporting this notion, we have 
reported that glucocorticoid therapy including methylprednisolone pulse therapy 
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reduced the renal expression of chemokines and their cognate receptors in accordance 
with the decrease in the clinical activities of human renal diseases (19-25). 
 
Chemokines/chemokine receptors in recent animal models 
Lessons from gene targeting mice 
 Data from gene targeting mice can give rise to the identification of the actions of 
chemokines and their cognate receptors (2).  Accumulating data suggest that 
chemokines and their cognate receptors expressed in the diseased kidneys govern 
critical aspects of acute and chronic renal inflammation leading to glomerulosclerosis 
and interstitial fibrosis (2).  Lack of CCR1 enhanced Th1 responses and glomerular 
injury induced by the administration of nephrotoxic serum (26).  Considering the 
expression of CCR1 on mesangial cells (15) and the probable involvement of CCR1 in 
interstitial fibrosis (24), CCR1 may protect glomerular and interstitial injury after the 
initial insults.  On the other hand, anti CCR1 antibodies significantly reduced the 
accumulation of inflammatory cells and collagen deposition, resulting in dramatic 
improvement of survival in bleomycin-induced lung fibrosis in mice (27).  The 
identification of organ- and phase-specific roles of CCR1 will be required.  Similarly, 
deleting MCP-1 dramatically reduces Mφ and T cell recruitment, protects kidney 
pathology, reduces proteinuria and prolongs survival in MCP-1-deficient MRL-Faslpr 
mice (28-29).  In contrast, the intensity of glomerulonephritis in CCR2 knockout mice 
was more severe induced by nephrotoxic serum.  This result suggests 
glomerulonephritis is not solely dependent on the presence of CCR2 for progression of 
disease and that the intriguing possibility that a CCR2 gene product ameliorates 
glomerulonephritis in this murine model. (30).  Further studies, therefore, will be 
required to identify the detailed molecular mechanisms of chemokine and chemokine 
receptor actions in renal diseases in vivo. 
 
Establishment of cell-mediated renal injury via ex-vivo gene transfer of chemokine 
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 Few studies revealed the direct evidence that locally or systematically produced 
chemokines in the kidneys induced the leukocyte infiltration and activation.  RANTES 
may explain the cellular infiltration including Th1 T cells in the interstitium in human 
renal diseases via its cognate receptors, CCR1 and CCR5 (24).  In addition, RANTES 
was upregulated in the kidneys of a murine lupus nephritis model, MRL-Faslpr mice 
prior to renal injury and increased with progressive injury (31). To explore whether 
locally produced RANTES incites renal injury with T cell infiltration, tubular epithelial 
cells genetically modified to secrete RANTES infused under the renal capsule incites 
interstitial nephritis in MRL-Faslpr mice  (31).  RANTES fostered the accumulation of a 
distinct subset of T cells (e.g. CD4 T cells), which would be compatible to clinical 
findings.  Supporting this notion, circulating components including CD4+ T cells are 
required to incite renal injury in MRL-Faslpr mice via both cellular and humoral 
immune responses (32).  The manipulation of T cells dependent on 
chemokines/chemokine receptors would be of therapeutic importance in renal diseases. 
 
Chemokines in human renal diseases  
Chemokine cascades 
 In inflammatory renal diseases, the types of leukocytes migrated to the diseased 
kidneys depend on the types of insults; neutrophils in acute inflammation, macrophages, 
lymphocytes and plasma cells in chronic inflammation, resulting in renal 
sclerosis/fibrosis.  To clarify the mechanism of specific leukocyte infiltration into the 
diseased kidneys and the involvement of chemokines and their cognate receptors in 
renal diseases, both urinary and plasma levels of chemokines were measured in patients 
with various renal diseases at different phases.  Firstly, urinary IL-8 levels were 
elevated in the acute phase and acute exacerbation of inflammatory renal diseases 
including IgA nephropathy, acute glomerulonephritis, lupus nephritis and crescentic 
glomerulonephritis (19-20).  Urinary levels of IL-8 were correlated with glomerular 
endocapillary proliferation and the degree of hematuria (19-20). Elevated urinary IL-8 
levels during the acute phase or exacerbation was found to be decreased during 
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spontaneous or glucocorticoid therapy-induced convalescence in all patients examined.  
Taken together, locally produced IL-8 in the diseased kidneys may reflect acute renal 
disease status based on leukocyte infiltration in the diseased kidneys (Table 1). 
 Secondly, urinary MCP-1 levels were significantly higher in patients with 
advanced renal diseases, and were correlated with pathological progressive factors such 
as mesangial proliferation, crescentic formation and interstitial lesions associated with 
CD68 positive Mφ in patients with IgA nephropathy, lupus nephritis, crescentic 
glomerulonephritis and other inflammatory renal diseases (20, 22-23).   
Urinary MCP-1 levels in lupus nephritis patients with active lesions were significantly 
higher than those with inactive lesions.  Moreover, elevated urinary MCP-1 levels were 
dramatically decreased during steroid therapy-induced convalescence.  
MCP-1 was mainly detected in vascular endothelial cells, tubular epithelial cells and 
infiltrated mononuclear cells in the interstitial lesions via both immunohistochemical 
and in situ hybridization analyses (20, 22-23).  Collectively, these observations suggest 
that MCP-1 is probably involved in the pathogenesis of progressive inflammatory renal 
diseases, especially tubulointerstitial lesions possibly through the recruitment and 
activation of Mφ.  Moreover, the measurement of urinary MCP-1 levels may be a useful 
clinical tool for monitoring the disease activity of inflammatory renal diseases (Figure 
1).  Considering the presence of chemokine amplification that C-X-C chemokines 
induced C-C chemokines and C-X-C chemokines as well in mesangial cells in vitro 
(16), Switches from acute inflammation to chronic inflammation in human renal 
diseases may be dependent on the subsequent expression of C-C chemokines (e.g. 
MCP-1) followed by C-X-C chemokines (e.g. IL-8).  In addition, MCP-1 mediates 
collagen deposition in experimental glomerulonephritis by TGF-β (33), MCP-1 
expression in chronic inflammation may result in renal sclerosis/fibrosis.  Supporting 
this notion, the administration of anti-MCP-1 antibodies prevented glomerular sclerosis 
and interstitial fibrosis as well  as the leukocyte infiltration (10).  Therefore, the 
possible positive amplification loop from C-X-C chemokines to C-C chemokines 
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resulting in sclerosis/fibrosis (“chemokine cascade”) may play a crucial role in the 
pathogenesis of human renal diseases (Table 1). 
 
MCP-1: a common regulatory molecule of chronic inflammation resulting in renal 
sclerosis/fibrosis 
 MCP-1 may be involved in progressive glomerular and interstitial damage 
resulting in renal sclerosis/fibrosis in inflammatory renal diseases.  Recent studies 
revealed that MCP-1 may play an important role in the pathogenesis of metabolic 
disorders, such as diabetic nephropathy and non-inflammatory nephrotic syndrome. 
Locally expressed MCP-1 in interstitium participates in human diabetic nephropathy 
especially in interstitial lesions via recruiting and activating Mφ (34).  Urinary MCP-1 
levels were significantly elevated in patients with diabetic nephrotic syndrome and 
advanced tubulointerstitial lesions.  Moreover, urinary levels of MCP-1 were well 
correlated with the number of CD68-positive infiltrating Mφ in the interstitium.  In 
contrast, serum MCP-1 levels remained as similar as those of healthy volunteers.  
Furthermore, MCP-1-positive cells were detected in the interstitium of diabetic 
nephropathy via both immunohistochemical and in situ hybridization analyses.  These 
observations suggest that locally produced MCP-1 may be involved in the development 
of advanced diabetic nephropathy, especially in the formation of tubulointerstitial 
lesions possibly through Mφ recruitment and activation.  In addition, overexpression of 
MCP-1  and other fibrogenic cytokines including platelet derived growth factor and 
TGF-β were associated with an interstitial accumulation of mononuclear cells and an 
increase in myofibroblastic activity in patients with membranous nephropathy, non-
inflammatory nephrotic syndrome (35). In contrast, patients with minimal change 
nephrotic syndrome showed undetectable levels of urinary MCP-1, similarly as those of 
healthy volunteers (22-23).  These results suggest that there might be no correlation 
between levels of urinary MCP-1 and proteinuria caused by non-inflammatory 
glomerular capillary lesions, such as minimal change nephrotic syndrome.  Therefore, 
some additional factors in patients with membranous nephropathy may be responsible 
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for the up-regulation of MCP-1 resulting in interstitial inflammation and fibrosis.  
Taken these together with the results in inflammatory renal diseases, up-regulation of 
MCP-1 may be a common regulatory pathway involved in the progressive renal damage 
with any etiologies leading to interstitial fibrosis (Figure 1).  Thus, the development of 
therapeutic approaches via MCP-1/its cognate receptors will be anticipated for the 
prevention of progressive renal injury in near future.  
 
Crescentic glomerulonephritis: Th1 type immune responses 
 In rapidly progressive glomerulonephritis, crescentic glomerulonephritis, 
associated with a comparable degree of tubulointerstitial nephritis and anemia, is a 
prominent feature which leads to eventual loss of renal function (23).  Therefore, 
specific molecule(s) involved in the pathogenesis and the development of clinical 
monitoring systems for disease activities are required for the better understanding of 
crescentic glomerulonephritis.  Urinary MIP-1α was specifically detected in patients 
with  crescentic glomerulonephritis, even though it was below detectable levels in 
healthy subjects and patients with renal diseases without crescentic formation (23).  
MIP-1α-positive cells were mainly detected in crescentic lesions.  In addition, recent 
studies revealed that chemokine receptors, CXCR3 and CCR5 are preferentially 
expressed on Th1 T cells (36-40).  CCR1, and CCR5-positive cells, cognate receptors 
for MIP-1α were detected in diseased glomeruli and interstitium (24). Using a dual 
staining technique, these positive cells were mainly CD3-positive T cells and CD68-
positive Mφ. Urinary MIP-1α levels in the patients with crescentic glomerulonephritis 
were well correlated with percentage of cellular crescent and the number of CD68 
positive infiltrating cells, CCR1 and CCR5 positive cells in the glomeruli (24).  
Moreover, elevated urinary levels of MIP-1α and the increased number of CCR5 
positive cells dramatically decreased during glucocorticoid therapy-induced 
convalescence.  These data suggest that MIP-1α may be involved specifically in the 
pathogenesis of crescentic glomerulonephritis via recruiting and activating Mφ and T 
cells as Th1 type immune responses and the measurement of urinary MIP-1α may be 
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the excellent system for monitoring the clinical activities of crescentic 
glomerulonephritis.  In contrast,  urinary MCP-1 levels were well correlated with the 
percentage of both total crescents and fibrocellular/fibrous crescents and the number of 
CD68-positive infiltrating cells in the interstitium.  Moreover, MCP-1 was detected 
mainly in the interstitium (23).  These observations suggest that locally produced MIP-
1α may be involved in the development of cellular crescents in acute phase via CCR1 
and CCR5 and that MCP-1 may be involved mainly in the development of interstitial 
lesions in the chronic phase when fibrocellular/fibrous crescents are present possibly 
through Mφ recruitment and activation. 
 
Chemokines and Th2-type immune responses 
 Little is known about chemokines/chemokine receptors toward Th2 immune 
responses in kidney diseases (40).  Locally produced eotaxin, the cognate ligand for 
CCR3, may contribute to renal eosinophil infiltration in the interstitium and that the 
elevated urinary levels of eotaxin fell dramatically during the glucocorticoid-induced 
convalescence, suggesting that they may reflect disease activities (41).  Further 
investigations would be informative for our understanding of host immune responses 
and renal diseases based on Th1/Th2 immune responses.   
  
Interstitial renal damage and chemokines 
 In addition to glomerular diseases, chemokines/chemokine receptor systems may 
be involved in interstitial renal diseases.  Recently, fractalkine expressed in the 
interstitium was reported to be involved leukocyte influx including CD16 positive cells 
(25).  Although, the intervention of fractalkine receptor, CX3CR1 showed the 
prevention of glomerular damage with the decrease in leukocyte infiltration (42), the 
blockade of fractalkine/its receptor may be beneficial to the prevention of interstitial 
damage as well as glomerular diseases.  In addition, MCP-1, as anticipated, was 
involved in the interstitial nephritis (43).  MCP-1 and other C-C chemokines were 
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involved in the pathogenesis of allograft rejection (44).  Interestingly, Met-RANTES 




Anti-chemokine therapy: novel therapeutic intervention to renal diseases  
 Based on in vitro and in vivo studies, selective intervention of 
chemokines/chemokine receptor systems and the adequate timing of anti-chemokine 
therapy may have the potential as the particular therapeutic strategies to combat with 
renal diseases culminating in renal sclerosis/fibrosis (46). 
 
Neutralizing antibodies against chemokines 
 The pathophysiological role of IL-8 was explored in animal model of acute 
immune complex-mediated glomerulonephritis by administering a neutralizing antibody 
against IL-8 (9).  Anti-IL-8 treatment decreased neutrophil number in glomeruli by 
40 % and dramatically prevented the fusion of epithelial cell foot process.  Furthermore, 
anti-IL-8 treatment completely reversed the urinary levels of protein and albumin to the 
normal levels.  In addition, the specific inhibition of MCAF/MCP-1 may prevent long-
term renal dysfunction in concomitant reduction of glomerulosclerosis and interstitial 
fibrosis in an animal model of crescentic glomerulonephritis (10).  Administration of a 
small dose of nephrotoxic serum induced severe proliferative and necrotizing 
glomerulonephritis, with crescentic formation in the early phase and glomerulosclerosis 
and interstitial fibrosis in the later phase in Wistar-Kyoto rats.  Anti-MCP-1 antibodies 
decreased the number of Mφ in glomeruli, proteinuria and crescentic formation. 
Furthermore, this treatment remarkably reduced glomerulosclerosis and interstitial 
fibrosis and improved renal function on day 56.  These results may suggest that 1) 
chemokines are essentially involved in the recruitment and activation of leukocytes in 
the diseased kidneys, 2) IL-8 and MCP-1 may be closely related to the function of 
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epithelial foot processes and the excreted amounts of protein, 3) MCP-1 may play an 
important role in the impairment of renal functions and renal sclerosis/fibrosis.  
 
Approaches via chemokine /chemokine receptor systems 
 Accumulating data suggest that the blockade of select chemokines and/or their 
cognate receptors provide the key to the improvement of renal diseases.  Antagonists 
against RANTES receptor using Met-RANTES (47) or APO-RANTES (48) decrease 
the cell infiltration in the diseased kidneys.  In addition, a natural viral chemokine 
receptor antagonist of viral origin, vMIP-II reduce proteinuria as well as cell infiltration 
(49).  Considering the importance of therapeutic approaches via chemokine/chemokine 
receptor systems in HIV infection, the development of these antagonists would be of 
use for the application to the renal diseases.   
 
p38 mitogen-activated kinases (MAPK) and chemokines 
 Mitogen-activated protein kinase (MAPK) signal transduction pathway is 
thought to be involved in proliferation and apoptosis in various types of inflammatory 
diseases (50). The activation of MAPK isoform p38, detected also in mesangial cells is 
closely related to apoptosis, stress responses and inflammation (50-51).  Moreover, the 
phosphorylation of p38 MAPK may contribute to the activation of nuclear factor (NF) 
κB and activating protein (AP) 1, which may be essentially involved in inflammatory 
processes.  FR167653 dramatically decreased the phosphorylation of p38 MAPK in 
cultured rat mesangial cells stimulated by interleukin-1β (our unpublished data).  The 
administration of FR167653 reduced glomerular damage, including crescentic 
formation and proteinuria (52).  In addition, FR167653 markedly decreased renal 
expression of MIP-1α and MCP-1. This study may provide evidence that p38 MAPK is 
a novel target for the therapy of glomerulonephritis. 
 
Other approaches to chemokine /chemokine receptor systems 
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 Agents that have impacts on cAMP (53) or NFκB such as antioxidants, 
glucocorticoids and aspirin can modulate chemokine expression, leading to improve 
renal pathology (54-55).  Furthermore, already available agents such as prostaglandin 
E1 (56) and AT1 receptor antagonist (57) and hydroxymethylglutaryl CoA reductase 
inhibitor (58) inhibit chemokine expression and cell infiltration.  Alternatively, the 
nonselective cyclooxygenase inhibitor upregulates chemokine expression (59).  The 
development of humanized monoclonal antibodies, particular antagonists against 
chemokines/chemokine receptors or chemokine-specific signal transduction that would 
block intrarenal chemokines could well provide significant beneficial effects in renal 
diseases. 
 
Concluding remarks and future directions 
 Based on the essential involvement of chemokine/chemokine receptor systems 
in the pathogenesis of phase-specific renal disorders, the intervention of 
chemokine/chemokine receptor systems may be therapeutically of importance to human 
renal diseases despite their redundancy.  Numbers of chemokine receptor antagonists as 
the therapeutic tool are under development.  Therefore, the selective blockade of 
chemokines/chemokine receptor systems may have the potential to become the 
particular therapeutic strategies in the specific phases of renal diseases in the near 
future.      
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